{"id":45292,"date":"2022-06-21T12:02:26","date_gmt":"2022-06-21T10:02:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/"},"modified":"2022-06-21T12:02:26","modified_gmt":"2022-06-21T10:02:26","slug":"cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/","title":{"rendered":"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis"},"content":{"rendered":"
\n

\nCarbon Biosciences is the first company to publicly launch from the Foundation\u2019s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation\u2019s therapeutics lab<\/i>\n<\/p>\n

<\/a><\/p>\n

BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company\u2018s preclinical research into an innovative gene therapy approach for cystic fibrosis. Carbon Biosciences is the first company to publicly launch from the Foundation\u2019s multi-million-dollar collaboration with Longwood Fund<\/a>, an early stage venture capital firm creating and investing in science-based companies that develop novel solutions to treat important unmet medical needs, and is part of the Foundation\u2019s Path to a Cure<\/a> initiative.<\/i>\n<\/p>\n

\nCarbon Biosciences began its scientific work in May at the CF Foundation Therapeutics Lab in Lexington, Mass., marking the first time the Foundation is hosting scientists from a startup company. As the Foundation expands its laboratory footprint later this summer, it will add space dedicated to incubating new companies focusing on CF research.\n<\/p>\n

\n\u201cBeing able to support Carbon Biosciences in its early stage research both financially and at our lab is an incredible step in evolving our investment strategy to attract the best science and technology to the CF space,\u201d said Martin Mense, PhD, senior vice president of drug discovery at the Foundation and head of the CF Foundation Therapeutics Lab. \u201cTheir unique scientific approach combined with our ability to help support their understanding of the challenges specific to CF biology could prove to be a giant step toward addressing the unmet need of innovative treatments in cystic fibrosis. It is our hope that they are the first of many companies we are able to incubate in the future.\u201d\n<\/p>\n

\nCarbon Biosciences aims to deliver a functional cystic fibrosis transmembrane conductance regulator (CFTR) gene directly into the lung cells of people with cystic fibrosis using a cutting-edge approach that has the potential to provide a treatment for all people living with CF, regardless of mutation. The hope is that this novel delivery method would circumvent the lungs\u2019 immune response, resulting in successful delivery of a functioning CFTR gene while also allowing redosing. Mense provided an overview of this approach during Plenary 1 of 2021\u2019s North American Cystic Fibrosis Conference.<\/a>\n<\/p>\n

\nTo learn more about the science of genetic therapies for CF, visit cff.org<\/a>.\n<\/p>\n

\nOur Investment Approach<\/b>\n<\/p>\n

\nThe Foundation’s venture philanthropy model provides companies early stage funding to develop breakthrough treatments for adults and children with cystic fibrosis. The approach has super-charged CF drug discovery and development by de-risking and accelerating new technologies in CF, resulting in more than 16 approved therapies \u2014 including four treatments for the underlying cause of CF.\n<\/p>\n

\nToday, the Foundation continues to evolve its venture philanthropy approach and invest more aggressively than ever before to support the development of the next generation of transformative therapies to help people with CF live their longest, healthiest lives possible. This approach includes incubating early stage research at the CF Foundation Therapeutics Lab, as well as collaborating with the University of California, Berkeley\u2019s Bakar Labs on a Golden Ticket Competition<\/a>.\n<\/p>\n

\nTo learn more about the Foundation\u2019s funding under its Path to a Cure <\/i>initiative, visit cff.org<\/a>.\n<\/p>\n

\nAbout the Cystic Fibrosis Foundation<\/b>\n<\/p>\n

\nThe Cystic Fibrosis Foundation is the world’s leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, visit cff.org<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Katie Haswell
\n
Email: khaswell@cff.org<\/a>
Phone: 240-200-3706\n<\/p>\n

\nIndustry<\/b>
Maria Wang
\n
Email: mwang@cff.org<\/a>
Phone: 240-200-3780\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Carbon Biosciences is the first company to publicly launch from the Foundation\u2019s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation\u2019s therapeutics lab BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company\u2018s preclinical research into an innovative … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-45292","format-standard","category-industry"],"yoast_head":"\nCystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Carbon Biosciences is the first company to publicly launch from the Foundation\u2019s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation\u2019s therapeutics lab BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company\u2018s preclinical research into an innovative ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-21T10:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220621005078\/en\/722999\/21\/CFF_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis\",\"datePublished\":\"2022-06-21T10:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/\"},\"wordCount\":667,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005078\\\/en\\\/722999\\\/21\\\/CFF_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/\",\"name\":\"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005078\\\/en\\\/722999\\\/21\\\/CFF_Logo.jpg\",\"datePublished\":\"2022-06-21T10:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005078\\\/en\\\/722999\\\/21\\\/CFF_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220621005078\\\/en\\\/722999\\\/21\\\/CFF_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/","og_locale":"en_US","og_type":"article","og_title":"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis - Pharma Trend","og_description":"Carbon Biosciences is the first company to publicly launch from the Foundation\u2019s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation\u2019s therapeutics lab BETHESDA, Md.–(BUSINESS WIRE)–The Cystic Fibrosis Foundation today announced its investment of $6 million in Carbon Biosciences to support the company\u2018s preclinical research into an innovative ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-21T10:02:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220621005078\/en\/722999\/21\/CFF_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis","datePublished":"2022-06-21T10:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/"},"wordCount":667,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621005078\/en\/722999\/21\/CFF_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/","url":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/","name":"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220621005078\/en\/722999\/21\/CFF_Logo.jpg","datePublished":"2022-06-21T10:02:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220621005078\/en\/722999\/21\/CFF_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220621005078\/en\/722999\/21\/CFF_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cystic-fibrosis-foundation-invests-6m-in-carbon-biosciences-to-advance-new-gene-therapy-approach-for-cystic-fibrosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45292"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45292\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}